Joshua Reed Buys 3,200 Shares of Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Stock

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) CFO Joshua Reed acquired 3,200 shares of the firm’s stock in a transaction on Thursday, September 5th. The stock was bought at an average price of $4.71 per share, with a total value of $15,072.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Shares of ALDX traded down $0.03 on Monday, reaching $4.90. The stock had a trading volume of 120,799 shares, compared to its average volume of 379,118. Aldeyra Therapeutics, Inc has a 12-month low of $4.31 and a 12-month high of $16.70. The firm has a market capitalization of $132.38 million, a price-to-earnings ratio of -2.74 and a beta of 0.61. The company has a 50-day simple moving average of $5.05 and a 200-day simple moving average of $6.88.

Aldeyra Therapeutics (NASDAQ:ALDX) last issued its quarterly earnings results on Thursday, August 8th. The biotechnology company reported ($0.49) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.51) by $0.02. As a group, sell-side analysts predict that Aldeyra Therapeutics, Inc will post -2.01 earnings per share for the current fiscal year.

ALDX has been the subject of several research analyst reports. ValuEngine raised shares of Aldeyra Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, June 22nd. Cantor Fitzgerald set a $33.00 price target on shares of Aldeyra Therapeutics and gave the company a “buy” rating in a research report on Tuesday, June 25th. Finally, Zacks Investment Research downgraded shares of Aldeyra Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 14th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. Aldeyra Therapeutics presently has an average rating of “Buy” and an average price target of $26.79.

Institutional investors have recently made changes to their positions in the business. Private Advisors LLC grew its position in shares of Aldeyra Therapeutics by 50.4% in the 1st quarter. Private Advisors LLC now owns 33,151 shares of the biotechnology company’s stock worth $299,000 after buying an additional 11,112 shares during the period. Ironwood Investment Management LLC purchased a new position in Aldeyra Therapeutics during the 1st quarter valued at about $116,000. National Asset Management Inc. boosted its stake in Aldeyra Therapeutics by 69.4% during the first quarter. National Asset Management Inc. now owns 27,006 shares of the biotechnology company’s stock worth $244,000 after acquiring an additional 11,066 shares in the last quarter. Thompson Siegel & Walmsley LLC bought a new stake in Aldeyra Therapeutics during the first quarter worth about $244,000. Finally, Prescott Group Capital Management L.L.C. bought a new stake in Aldeyra Therapeutics during the first quarter worth about $948,000. 61.26% of the stock is owned by institutional investors and hedge funds.

About Aldeyra Therapeutics

Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.

Recommended Story: Why does the United States have a lingering trade deficit?

Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with's FREE daily email newsletter.